Thelansis’s “Gaucher Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Gaucher disease is the most common lysosomal storage disorder, caused by autosomal recessive mutations in the GBA1 gene encoding glucocerebrosidase. This deficiency drives the progressive intralysosomal accumulation of glucosylceramide within reticuloendothelial macrophages, forming lipid-laden “Gaucher cells.” The disease spans three subtypes: Type 1 (non-neuronopathic and most prevalent), Type 2 (acutely fatal infantile neuronopathic), and Type 3 (chronic neuronopathic). Systemic features include hepatosplenomegaly, anemia, thrombocytopenia, and skeletal damage like avascular necrosis, while oculomotor apraxia and ataxia track with neuronopathic forms. Diagnosis utilizes dried blood spot enzyme assays, GBA1 genotyping, and sensitive plasma biomarkers like glucosylsphingosine (lyso-Gb1). Traditional enzyme replacement therapies (imiglucerase, velaglucerase alfa, taliglucerase alfa) and oral substrate reduction therapies (eliglustat, miglustat) effectively reverse visceral and bone disease but fail to cross the blood-brain barrier. However, the therapeutic landscape has reached a historic inflection point: the FDA granted Priority Review to Sanofi’s brain-penetrant oral glucosylceramide synthase inhibitor venglustat, setting a regulatory decision date for November 25, 2026. Backed by Phase 3 LEAP2MONO success, venglustat stands to become the first approved modifier of neurological decline in Type 3 disease, radically shifting long-term prognosis.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Gaucher Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Gaucher Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.